• Vaccine Name: Vaccina Virus Vaccine A27/B5/CpG7909
• Target Pathogen: Vaccinia virus
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: Mouse
• Antigen: B5, A27 (Reeman et al., 2017)
• A27L gene engineering:
  • Type: Recombinant protein preparation
  • Description: (Reeman et al., 2017)
  • Detailed Gene Information: Click Here.
• B5R gene engineering:
  • Type: Recombinant protein preparation
  • Description: (Reeman et al., 2017)
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: Vaccinia virus protein subunits with a CpG adjuvant protects mice from lethal Vaccine Virus infection. (Reeman et al., 2017)

Mouse Response

• Vaccination Protocol: Mice were vaccinated with combinations of VACV proteins adjuvanted with alhydrogel or CpG7909; control VACV Lister; or PBS. Animals received 3 immunizations with proteins, at 21-day intervals. (Reeman et al., 2017)
• Challenge Protocol: VACV IHD suspended in PBS was administered in 10 μL to a single nares without anesthesia. Each mouse received 5 × 10^6 pfu of virus, equivalent to 100× the median lethal dose. The weight of each mouse was recorded daily. (Reeman et al., 2017)
• Efficacy: The combination of B5 and A27 proteins adjuvanted with CpG oligodeoxynucleotides (ODN) gives a level of protection in mice that is equivalent to the Lister traditional vaccine in a lethal vaccinia virus challenge model. (Reeman et al., 2017)